for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

180 Life Sciences Corp

ATNF.OQ

Latest Trade

10.15USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.91

 - 

13.04

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
10.15
Open
--
Volume
--
3M AVG Volume
51.50
Today's High
--
Today's Low
--
52 Week High
13.04
52 Week Low
1.91
Shares Out (MIL)
24.11
Market Cap (MIL)
257.29
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

KBL Merger Corp IV SPAC Signs Definitive Business Combination Agreement To Acquire Cannbiorx Life Sciences

Kbl Merger Corp. Iv Spac Announces Non-Binding Term Sheet To Acquire Cannbiorx Life Sciences Corp. And Its Three Interactive Programs

KBL Merger prices its IPO of 10 mln units at $10 per unit

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About 180 Life Sciences Corp

180 Life Sciences Corp., (180 Life Sciences) formerly KBL Merger Corp. IV., is a research and development company. The Company is focused on research into solving one of the diseases is inflammation. The Company consists of three programs developing drugs in separate areas of inflammation. The Company’s pipeline, including Fibrosis and Anti-TNF, SCAs and a7nAChR. The Fibrosis and Anti-TNF treats diseases like Dupuytren’s contracture, frozen shoulder, polycystic ovarian disease (POCD), nonalcoholic steatohepatitis (NASH). The SCAs includes chronic pain and early arthritis. The a7nAChR includes smoking cessation induced ulcerative colitis.

Industry

Business Services

Contact Info

830 MENLO AVENUE, SUITE 100

MENLO PARK, CA

94025

United States

+1.650.5070669

https://180lifesciences.com/

Executive Leadership

Marc Feldmann

Co-Executive Chairman of the Board

Lawrence Steinman

Co-Executive Chairmen of the Board

James N. Woody

Chief Executive Officer, Director

Ozan Pamir

Interim Chief Financial Officer

Jonathan Rothbard

Chief Scientific Officer

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
12.29
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
55.15
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-34.72
Return on Equity (TTM)
-29.69

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up